0000899243-21-039338.txt : 20211005
0000899243-21-039338.hdr.sgml : 20211005
20211005195032
ACCESSION NUMBER: 0000899243-21-039338
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211005
FILED AS OF DATE: 20211005
DATE AS OF CHANGE: 20211005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BORMANN-KENNEDY BARBARA-JEAN ANNE
CENTRAL INDEX KEY: 0001635065
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40880
FILM NUMBER: 211308418
MAIL ADDRESS:
STREET 1: 1188 BROADWAY, SUITE 306
CITY: SOMERVILLE
STATE: MA
ZIP: 02144
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc.
CENTRAL INDEX KEY: 0001867096
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 N. LASALLE STREET, SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
BUSINESS PHONE: 844-445-5704
MAIL ADDRESS:
STREET 1: 180 N. LASALLE STREET, SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-10-05
0
0001867096
Xeris Biopharma Holdings, Inc.
XERS
0001635065
BORMANN-KENNEDY BARBARA-JEAN ANNE
C/O XERIS BIOPHARMA HOLDINGS, INC.
180 N. LASALLE STREET, SUITE 1600
CHICAGO
IL
60601
1
0
0
0
Stock Option (Right to Buy)
12.50
2021-10-05
4
A
0
19650
A
2028-05-15
Common Stock
19650
19650
D
Stock Option (Right to Buy)
10.00
2021-10-05
4
A
0
20000
A
2029-02-27
Common Stock
20000
20000
D
Stock Option (Right to Buy)
4.68
2021-10-05
4
A
0
11228
A
2030-06-04
Common Stock
11228
11228
D
Stock Option (Right to Buy)
3.90
2021-10-05
4
A
0
11228
A
2031-06-08
Common Stock
11228
11228
D
On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction").
(Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option.
These options are fully vested as of the date hereof.
Such options will vest in full upon the earlier to occur of June 8, 2022 or the date of the Company's next annual meeting of stockholders.
/s/ Beth Hecht, as Attorney-in-Fact
2021-10-05